1. Clenbuterol has been proposed for the treatment of muscle wasting disorders, but its long-term effects on skeletal muscle function have not been tested rigorously. We tested the hypothesis that year-long treatment of young (6 months) mice with clenbuterol would increase skeletal muscle mass and in vitro measurements of specific force (Po) and power output.
INTRODUCTION
Treatment with the ␤2-adrenoceptor agonist clenbuterol produces significant increases in muscle mass and the muscle mass-body mass ratio (relative mass) in a number of different species. 1 Consequently, clenbuterol has been proposed as a treatment to offset muscle atrophy associated with such conditions as ageing, 2 denervation 3-5 and immobilization or muscle unloading. 6 The mechanism by which clenbuterol produces the hypertrophy of skeletal muscle is unclear, but increased protein synthesis, decreased protein degradation or a combination of the two have been proposed. 7, 8 Based on its anabolic properties, clenbuterol treatment has been recommended for humans suffering from muscle wasting diseases, such as muscular dystrophy, 9, 10 even though the long-term effects have not been established. In particular, muscle hypertrophy in the absence of any improvement in muscle function would be of only cosmetic significance, yet the impact of long-term clenbuterol treatment on the maximum force or power of skeletal muscles 11 of either control or impaired skeletal muscles has received only limited attention. 12 The purpose of the present study was to investigate the effects of year-long treatment with clenbuterol on the structure and function of skeletal muscles of mice. We tested the hypothesis that 52 weeks treatment of mice with clenbuterol would increase absolute and relative masses of heart and skeletal muscles, increase the absolute maximum force and power output of fast extensor digitorum longus (EDL) and slow soleus muscles and increase the specific maximum force production and normalized maximum power output of EDL muscles, soleus muscles and strips of diaphragm (DPM) muscles.
METHODS

Animal groups and drug administration
Young adult (6-month-old) male specific pathogen-free (SPF) C57BL/10ScSn mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and housed in barrier-protected facilities of the Unit for Laboratory Animal Medicine at The University of Michigan. Mice were provided with standard laboratory chow and water ad libitum. All experiments were conducted in accordance with the guidelines outlined by the National Institutes of Health. 13 Mice were separated into either treated or untreated groups and were housed in pairs or three to a cage. Long-term daily treatment with clenbuterol produces less hypertrophy than a staggered schedule of administration. [14] [15] [16] Consequently, treated mice were given clenbuterol (Sigma Chemical Co., St Louis, MO, USA; 1.5-2 mg/kg per day) in their drinking water, every day for the first week and then followed a staggered 3 day on/3 day off schedule for the remainder of the 52 week protocol. To attenuate the response to clenbuterol even further, treatment was suspended for 7 days every 6 weeks. (approximately 400 mL/kg) 15 and a concentration (5 mg/mL) that has been shown previously to produce a maximal effect of the ␤2-adrenoceptor agonist on skeletal muscle. [15] [16] [17] The efficacy of clenbuterol administration via the drinking water has been well established. 8 In our hands, the life span of C57BL/10ScSn mice housed under SPF conditions exceeds 28 months of age. Therefore, by the end of the 12 month clenbuterol treatment period, the mice would be considered to be older adult but not aged animals. Generally, age-related changes in structure-function relationships of skeletal muscles from these mice are not apparent until after 24 months of age.
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Measurement of contractile properties
Two days after the last treatment period, mice were anaesthetized with sodium pentobarbitone (70 mg/kg, i.p.), with supplemental doses administered as necessary to maintain adequate anaesthesia such that no response to tactile stimuli was observed. The fast EDL and slow soleus muscles from the left hindlimb were carefully excised tendon-to-tendon. In addition, the contractile properties of DPM muscle strips were investigated using techniques described previously. 18 A silk suture was tied to each tendon of the isolated muscles, which were placed into a Plexiglass chamber filled with Ringer solution (containing (in mmol/L): NaCl 137; NaHCO3 24; glucose 11; KCl 5; CaCl2 2; MgSO4 1; NaH2PO4 1; tubocurarine chloride 0.025), pH 7.4, oxygenated with 95% O2 and 5% CO2 and maintained at 25°C. Muscles were aligned horizontally between a servomotor lever arm (model 300H; Cambridge Technology Inc., Watertown, MA, USA) and the stainless steel hook of a force transducer (model BG-50; Kulite Semiconductor Products Inc., Leonia, NJ, USA) and field stimulated by pulses transmitted between two platinum electrodes placed longitudinally either side of the muscle. Square wave pulses (0.2 ms duration) generated by a stimulator (model S88; Grass Instruments, Quincy, MA, USA) were amplified (model DC-300A Series II; Crown International Inc., Elkhart, IN, USA) to increase and sustain current intensity to a sufficient level to produce a maximum isometric tetanic contraction. 18 Stimulation voltage and muscle length (Lo) were adjusted to obtain maximum isometric twitch force. Optimum fibre length (Lf) was determined by multiplying Lo by previously determined fibre length to muscle length ratios of 0.44 for the EDL and 0.71 for the soleus muscle 19 and 1.0 for the DPM. 18 Maximum tetanic force production (Po) was determined from the plateau of the frequency-force relationship.
Power output was determined by isovelocity shortenings during maximum muscle activation. Initiation of the isovelocity shortening ramp and stimulation of the muscle occurred simultaneously. Stimulation was terminated at the end of the shortening ramp and the muscle was held isometric for 100 ms, allowing it to relax before returning to resting length. Maximum power output was calculated as the product of average force and velocity of shortening. The average force generated during the shortening ramp was determined by integrating the area under the force curve and dividing by the elapsed time. The optimum shortening velocity (Vopt) was defined as the velocity that resulted in maximum power. 20 Specific force (kN/m 2 ) values were normalized to mean total muscle fibre cross-sectional area (CSA), while power (W) was normalized by muscle mass (W/kg). After the contractile properties were measured, muscles were trimmed of their tendons and visible connective tissue and were weighed on an analytical balance (Mettler AE-50, Toledo, OH, USA). The total fibre CSA of each muscle was determined by dividing muscle mass by the product of Lf and 1.06 mg/mm 3 (the density of mammalian skeletal muscle). In addition, the heart and the tibialis anterior muscles were removed, blotted and weighed. The relative muscle mass of the heart and of each skeletal muscle was calculated as the muscle mass expressed as a proportion of the body mass.
Statistical analysis
Results are presented as the meanϮSEM. Using N C S S software (Number Cruncher Statistical System 5.01, Kaysville, UT, USA), differences between treated and untreated groups were assessed using Student's t-test. Significance was set a priori at P < 0.05.
RESULTS
Effect of clenbuterol treatment on muscle masses
After 1 year clenbuterol treatment, the body masses of treated mice were not different from those of untreated mice (Table 1 ). In contrast, for treated compared with untreated mice, absolute muscle mass and relative muscle mass were greater for the heart (28 and 15%, respectively) and for each of the three skeletal muscles (EDL: 12 and 18%, respectively; soleus: 12 and 18%, respectively; tibialis anterior 17 and 12%, respectively).
Effect of clenbuterol treatment on force and power output of skeletal muscles
For EDL and soleus muscles from treated and untreated mice, absolute Po (mN) and absolute power output (mW) were not different (Table 2 ). For the EDL muscles of treated mice, the Vopt was lower than that of untreated mice, but the power was unaffected because of a higher average force. For the soleus muscles and DPM strips, no differences were observed in Vopt. The administration of clenbuterol had no effect on the specific Po (kN/m 2 ) or normalized power output (W/kg) of the EDL muscles, soleus muscles or DPM muscle strips (Table 2) .
DISCUSSION
Heart and skeletal muscle masses
As reported previously by a number of investigators, 1-3,7-9,12,14 the administration of clenbuterol increased absolute muscle mass and the muscle mass-body mass ratio of fast and slow skeletal muscles from 12 to 18%, with the mass of the heart muscle increased to an even greater extent. The percentage increase in the soleus muscle was not different from increases reported after shorter periods (20 weeks) of administration. 15 The percentage increase in the EDL muscle was greater in the present study (52 weeks of treatment) compared with the increase reported by Hayes and Williams 15 following 20 weeks of administration, which suggests that the effectiveness of clenbuterol in increasing muscle mass continues for the duration of the treatment period. The changes in composition of the muscle fibre types are much more variable and do not appear to be of any functional significance. Values for heart mass/body mass are expressed as (g/g) ϫ 100; values for other muscle mass/body mass are expressed (mg/g) ϫ 1000. *P < 0.05 for differences between muscles of treated and untreated mice. EDL, extensor digitorum longus.
16,21-23
Contractile properties
Considerable controversy exists as to the effect of clenbuterol on the development of absolute and specific Po. Short periods (14 days) of clenbuterol treatment did not alter the absolute or specific Po of rat medial gastrocnemius muscle 24 or the gastrocnemiusplantaris-soleus muscle complex. 23 Longer periods of administration (up to 20 weeks) also have not altered the absolute or specific Po of the EDL muscle from rats or mice. 3, 15 The effect of similar shorter periods (up to 20 weeks) of clenbuterol administration on the absolute or specific Po of the soleus muscle has produced conflicting results. 3, 15, 16 Our observation of a small but significant increase in absolute Po of the soleus muscle following year-long clenbuterol treatment is consistent with the data of Dupont-Versteegden et al., 12 who reported an increase in absolute Po of the EDL muscles obtained from control (C57BL/10SNJ) mice and those subjected to 1 year continuous treatment with clenbuterol (1.0-1.5 mg/g per day) in the drinking water. Similarly, our data are in good agreement with the conclusion of these investigators 12 that clenbuterol produced no change in the specific Po of soleus muscles or DPM muscle strips. Based on our data and the supportive observations of other groups, we conclude that clenbuterol treatment, even of year-long duration, has only a minor effect on the absolute force of slow, but not fast, skeletal muscles and has no effect on the specific force production of fast or slow skeletal muscles.
One of the most important capabilities of skeletal muscles is to do work and generate power. 11 The effect of clenbuterol on the power output of fast and slow skeletal muscles has not been reported previously. Assuming that the anabolic and lipolytic effects of clenbuterol 7, 25 will also enhance performance, clenbuterol is frequently used by athletes, especially those involved in strength-and power-related sports. 26 The year-long treatment with clenbuterol of young mice, with significant muscle hypertrophy but no evidence of any increase in normalized force or power of either fast or slow skeletal muscles, provides no support for such an assumption.
CONCLUSIONS
Because all physical activities require muscles to generate force and power, 20, 27 an increase in muscle mass in the absence of functional improvement is of no consequence. Despite several studies suggesting that clenbuterol has therapeutic potential for treating muscle wasting disorders, 9,10 few investigators have studied the long-term effects of ␤2-adrenoceptor agonist administration on skeletal muscle function. 12 Year-long treatment with clenbuterol increased skeletal muscle mass, but did not alter either the specific Po or absolute or normalized power output of EDL, soleus or DPM muscles. The lack of improvement in contractile function following year-long administration of clenbuterol, despite the increases in muscle mass, indicates that clenbuterol has little long-term therapeutic potential for improving muscle contractility. For diaphragm muscle strips (DPM), the width and thickness and, consequently, mass vary among animals at the discretion of the surgeon excising them. Hence, absolute forces and powers developed by DPM have no physiological meaning and comparisons can only be made after the forces and powers have been normalized for total fibre cross-sectional area (kN/m 2 ) and mass (W/kg), respectively. 18 *P < 0.05 for differences between muscles of treated and untreated mice. Lf, muscle fibre length; Po, tetanic force; Vopt, optimum velocity for maximum power output; N/A, not applicable.
